LIPTRUZET (ezetimibe/atorvastatin), fixed combination of cholesterol-lowering drugs

CARDIOLOGY - New medicinal product

Opinions on drugs - Posted on Feb 29 2016

Inclusion

LIPTRUZET has a Marketing Authorisation, as adjunctive therapy to diet, in adults with hypercholesterolaemia (heterozygous or homozygous familial, or non-familial) or mixed dyslipidaemia when the ezetimibe + atorvastatin combination is indicated.
The efficacy of the combination (free or fixed) of ezetimibe with atorvastatin has been demonstrated only on a biological criterion, the reduction of LDL cholesterol (LDL-c) levels.
The efficacy in terms of morbidity and mortality has not been demonstrated to date.
No clinical data studying the efficacy of the fixed combination is currently available.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account